Printer Friendly

ZONAGEN, INC. NAMES LOUIS PLOTH, JR. AS CHIEF FINANCIAL OFFICER; FORMER CFO OF UNISYN TECHNOLOGIES, INC.

 THE WOODLANDS, Texas, Nov. 2 /PRNewswire/ -- Zonagen, Inc. (NASDAQ: ZONA; Pacific: ZNG) today announced that Louis Ploth, Jr., has been named as the company's chief financial officer. For the past seven years, Ploth has held senior financial management positions in the biotechnology industry with Synbiotics Corporation(NMS: SBIO) and its spin-off Unisyn Technologies, Inc., serving most recently as vice president, finance and administration and chief financial officer for Unisyn Technologies in Tustin, California.
 "Louis' biotechnology experience ranges from initiating sound fiscal programs for start-up companies to developing growth strategies for start-ups making the transition into fully integrated biopharmaceutical companies. He has a successful track record implementing programs for public and private financing, as well as executing licensing and acquisition agreements," said Joseph S. Podolski, Zonagen's president. "We're confident that Louis will make an immediate contribution to the company's development, and we welcome him to Zonagen's management team."
 From 1986 to 1991, Ploth served as corporate controller for San Diego-based Synbiotics Corporation. Previously, he held a number of finance and accounting positions with Plant Industries, Inc., serving most recently as corporate controller. Ploth has a bachelor's degree in business administration from Montclair State College in Montclair, New Jersey.
 Zonagen is engaged in the development of products for reproductive health. The company's first products will originate from its proprietary and patented technology relating to the zona pellucida, the protein-rich shell surrounding a mammalian egg. Zonagen has adopted a business strategy that seeks to establish the validity of its technology in veterinary markets that are relatively easy to access, while simultaneously developing major products for human use.
 -0- 11/2/93
 /CONTACT: Joseph S. Podolski, president of Zonagen, 713-367-5892; or Chris Taylor, account executive of Feinstein Partners,617-577-8110, for Zonagen./
 (ZONA SBIO)


CO: Zonagen, Inc.; Synbiotics Corporation, Unisyn Technolgies, Inc.;
 Plant Industries, Inc. ST: Texas, California IN: MTC SU: PER


JL -- NE001 -- 9491 11/02/93 08:43 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 2, 1993
Words:316
Previous Article:STATORDYNE CORP. ANNOUNCES ADDITIONAL SALES AND PATENT AWARD
Next Article:CORTEX PHARMACEUTICALS ANNOUNCES PRE-CLINICAL RESULTS WITH MEMORY ENHANCEMENT DRUG AND VASOSPASM COMPOUNDS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters